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Background: Normal pressure hydrocephalus (NPH) is most common in the elderly and has a high co-morbidity
with Alzheimer’s disease (AD) and cerebrovascular disease (CVD). To understand the relationship between NPH, AD
and CVD, we investigated how chronic hydrocephalus impacts brain amyloid-beta peptide (Aβ) accumulation and
vascular pathology in an AD transgenic rodent model. Previously we showed that the altered CSF physiology
produced by kaolin-hydrocephalus in older wild-type Sprague–Dawley rats increased Aβ and hyperphosphorylated
Tau (Silverberg et. al. Brain Res. 2010, 1317:286–296). We postulated that hydrocephalus would similarly affect an
AD rat model.
Methods: Thirty-five transgenic rats (tgAPP21) that express high levels of human APP and naturally overproduce
Aβ40 were used. Six- (n = 7) and twelve-month-old (n = 9) rats had hydrocephalus induced by cisternal kaolin
injection. We analyzed Aβ burden (Aβ40, Aβ42 and oligomeric Aβ) and vascular integrity (Masson trichrome and
Verhoeff-Van Gieson) by immunohistochemistry and chemical staining at 10 weeks (n = 8) and 6 months (n = 5)
post hydrocephalus induction. We also analyzed whether the vascular pathology seen in tgAPP21 rats, which
develop amyloid angiopathy, was accelerated by hydrocephalus. Age-matched naïve and sham-operated tgAPP21
rats served as controls (n = 19).
Results: In hydrocephalic tgAPP21 rats, compared to naïve and sham-operated controls, there was increased Aβ 40
and oligomeric Aβ in hippocampal and cortical neurons at 10 weeks and 6 months post-hydrocephalus induction.
No dense-core amyloid plaques were seen, but diffuse Aβ immunoreactivity was evident in neurons. Vascular
pathology was accelerated by the induction of hydrocephalus compared to controls. In the six-month-old rats,
subtle degenerative changes were noted in vessel walls at 10 weeks post-kaolin, whereas at six months post-kaolin
and in the 12-month-old hydrocephalic rats more pronounced amyloid angiopathic changes were seen, with
frequent large areas of infarction noted.
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Conclusions: Kaolin-hydrocephalus can accelerate intraneuronal Aβ40 accumulation and vascular pathology in
tgAPP21 rats. In addition, disrupted CSF production and reduced CSF turnover results in impaired Aβ clearance and
accelerated vascular pathology in chronic hydrocephalus. The high co-morbidity seen in NPH, AD and CVD is likely
not to be an age-related coincidence, but rather a convergence of pathologies related to diminished CSF clearance.
Keywords: Normal pressure hydrocephalus, Transgenic rat, Kaolin-induced hydrocephalus, Amyloid-beta peptide,
Cerebrovascular disease, Amyloid angiopathy, Solute clearance, CSF circulationBackground
Normal pressure hydrocephalus (NPH) is a clinically-
diagnosed disease that presents with one or several
symptoms and signs, including gait disturbance, incon-
tinence and dementia [1]. The gait disturbance is de-
scribed as a gait apraxia (magnetic gait), and the urinary
incontinence is often nocturnal. There is an associated
ventricular enlargement, usually involving all ventricles,
and some enlargement of the subarachnoid space (SAS)
over the convexities. There is usually intermittent eleva-
tion of the cerebrospinal fluid (CSF) pressure most often
at night and often during rapid eye movement (REM)
sleep [2-4]. Clinical diagnosis rests on clinical and radio-
logic findings as well as the effects of large volume CSF
removal [5].
Although there is no pathological finding that con-
firms the clinical diagnosis of NPH on brain biopsy or
at post-mortem, there is often evidence for both
Alzheimer’s disease (AD) and cerebrovascular disease
(CVD) with a frequency that precludes the idea that
these are unrelated afflictions of the elderly [6-9]. In-
deed, initially these findings were thought to be simply
unrelated coincidental diseases of the elderly, but that
is no longer tenable.
In patients with the symptoms and signs of NPH,
there is a very high co-morbidity with both AD and
CVD. The incidence of AD pathology in patients with
NPH is much higher than expected if the two diseases
were unrelated diseases of advancing age. For instance,
anywhere from 25% to 75% of NPH patients will have
evidence of AD pathology, depending upon the degree
of dementia, on brain biopsy at the time of shunt place-
ment or at autopsy [10-12]. In aging, only 10% of sub-
jects over 65 will have clinical or histological evidence of
AD [13]. Evidence of CVD is similarly increased in NPH
over normally aged subjects.
Alzheimer’s disease is characterized by amyloid pla-
ques (neuritic or dense-core), composed of amyloid-beta
peptides (Aβ) and neurofibrillary tangles made up of
paired helical filaments of hyperphosphorylated tau pro-
tein (pTau). Amyloid angiopathy is also characteristic of
AD brains. This vascular pathology is characterized by
vascular deposition of Aβ [14,15]. In recent years it has
become accepted that the accumulation of Aβ in non-familial AD is due to an inability to clear these peptides
from the brain, rather than an overproduction as seen in
familial AD [16-18].
In previous reports, it was shown that both Aβ and
pTau protein accumulated in older (12 months) wild-
type Sprague–Dawley rats, rendered hydrocephalic by
intra-cisternal injection of kaolin, in concentrations sig-
nificantly higher than age-matched and sham-operated
controls [19,20]. In this histological and immunohisto-
chemical study we report the effects of induced hydro-
cephalus on a transgenic rat model of AD (tgAPP21): a
double transgenic (Sw/Ind mutant) human amyloid pre-
cursor protein (APP) construct that expresses high levels
of human APP and Aβ40 [21]. Our hypothesis was that if
the CSF was not an important clearance pathway for Aβ
removal from the brain, then the accumulation of Aβ
would be the same between hydrocephalic and control
tgAPP21 rats. We found that the hydrocephalic tgAPP21
rats accumulated Aβ40 and oligomeric Aβ, as well as
manifesting evidence of vascular disease and ische-
mic infarction, well before age-matched and sham-
operated controls. Cortical infarction was seen only
in the hydrocephalic rats.Methods
Animals
Breeding pairs of APP 21 transgenic rats (tgAPP21) were
obtained from the Department of Veterinary Pathobiol-
ogy at the University of Missouri. These rats express
high levels of human APP and naturally overproduce
Aβ40, but not Aβ42. The tgAPP21 rats were produced
from inbred Fischer 344 rats that express human APP
driven by the ubiquitin-C promoter. They were gener-
ated via lentiviral vector infection of the Fischer 344 zy-
gotes [21]. Immunohistochemistry in brain showed that
the human APP transgene was expressed in neurons,
but not in glial cells. After quarantine, the tgAPP21 rats
were allowed to breed normally. The rats were housed
in the veterinary care facility of the Aldrich Laboratories
at Rhode Island Hospital and had food and water ad lib.
All experiments were approved by the Institutional
Animal Care and Use Committee (IACUC) at Rhode
Island Hospital.
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kaolin (aluminum silicate 0.9%). The technique has been
previously published [19,20,22]. Thirty-five tgAPP21 rats
were used in these studies. Six-month (n = 7) and
twelve-month-old (n = 9) rats had hydrocephalus in-
duced by cisternal kaolin injection. After 10 weeks or six
months of hydrocephalus the rats were euthanized by
intra-peritoneal pentobarbital injection (125 mg/kg).
Age-matched naïve and sham-operated tgAPP21 rats
served as controls (n = 19) and their brains were proc-
essed in exactly the same way. Three of the 12-month-
old hydrocephalic rats and four of the controls were
allowed to survive to a natural death to assess the ef-
fects of the vascular changes on brain parenchyma
(see Table 1).
After intracardiac cannulation and perfusion with
phosphate-buffered saline, the brains were removed and
immersed in 4% paraformaldehyde. Following standard
tissue processing and paraffin embedding procedures,
coronal brain sections were serially cut at 8 μm starting
from the level of the median eminence. Ventricular en-
largement was measured by the Evans ratio for control
rats compared to rats at 10 weeks post hydrocephalus
induction. The maximum ventricular diameter on cor-
onal section at the bregma was divided by the maximum
brain diameter on the post-mortem brain sections.
We analyzed Aβ burden by immunohistochemistry
(Aβ40, Aβ42 and oligomeric Aβ), and vascular integrityTable 1 Summary of experimental animals and histological fi





6 mo. + 10 wk. Kaolin 4 ++ +++
6 mo. + 10 wk. Sham 2 - -
6 mo. + 10 wk. Naïve 2 - -
6 mo. + 6 mo. Kaolin 3 + +
6 mo. + 6 mo. Sham 2 - -
6 mo. + 6 mo. Naïve 2 - -
12 mo. + 10 wk. Kaolin 4 ++ +++
12 mo. + 10 wk. Sham 2 - -
12 mo. + 10 wk. Naïve 2 - -
12 mo. + 6 mo. Kaolin 2 + +
12 mo. + 6 mo. Sham 2 - -
12 mo. + 6 mo. Naïve 1 - -
12 mo. to natural
end-of-life
Kaolin 3 + +
12 mo. to natural
end-of-life
Sham 2 - -
12 mo. to natural
end-of-life
Naïve 2 - -
The pathology and morphological changes, as observed in histochemically-stained
changes (−) to mild (+), moderate (++), or severe (+++) changes.by histochemical staining (Masson trichrome and
Verhoeff-Van Gieson) at 10 weeks (n = 8) and six
months (n = 5) post hydrocephalus induction. We also
analyzed whether the vascular pathology seen in
tgAPP21 rats, which normally develop amyloid angiopa-
thy, was accelerated by hydrocephalus. Age-matched naïve
and sham-operated tgAPP21 rats served as controls
(n = 15).
Immunohistochemistry
Eight μm-thick tissue sections (on poly-L-lysine-coated
slides) were incubated in an oven at 60°C for 1 hour, and
after deparaffinization and rehydration, sections were
treated with hot (85°C) 10 mM citrate buffer, pH 6, for
15 minutes. Sections were washed with distilled water
and then quenched with a dual endogenous enzyme-
blocking reagent (Dako, Carpinteria, CA, USA; Catalog
#S2003) for 10 minutes at room temperature to elim-
inate endogenous peroxidase activity. After washing in
0.05 M Tris-buffered saline with 0.05% Tween-20
(TBST), pH 7.6, sections were incubated overnight at
4°C with rabbit polyclonal antibodies directed against
Aβ40 (Alpha Diagnostic International, San Antonio, TX,
USA; Catalog #BAM401-A, diluted 1:100), Aβ42 (Alpha
Diagnostic International; Catalog #BAM421-A, diluted
1:200), or oligomeric Aβ (A11; Chemicon, Temecula,
CA, USA; Catalog #AB9234, diluted 1:2000). After
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sections, were qualitatively graded using a scale ranging from no detectable
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bodies (anti-rabbit; Dako; Catalog #K4002) was applied
for 30 minutes at room temperature, in accordance
with the EnVision + System for immunohistochemical
staining. The tissue sections were washed in TBST and
then the immunoreaction product was developed using
3,3-diaminobenzidine (Dako; Catalog #K3468) as the
chromogen. Sections were dehydrated through a series
of graded alcohols back to xylene, and then cover-
slipped and sealed using Cytoseal XYL (Richard-Allan
Scientific, Kalamazoo, MI, USA; Catalog #8312-4). Pri-
mary antibody omission controls were run alongside
the other samples to check for non-specific binding due
to the secondary antibodies, and advanced AD human pre-
frontal cortical sections were run as positive controls. In
place of using a counterstain on immunohistochemically-
stained slides, adjacent serial sections were stained with
hematoxylin and eosin (H&E) for analysis of general
tissue morphology.Immunofluorescence
Following deparaffinization and rehydration, tissue sec-
tions were treated with hot (85°C) 10 mM citrate buffer,
pH 6, for 15 minutes. Sections were washed with dis-
tilled water and then quenched with a dual endogenous
enzyme-blocking reagent (Dako) for 10 minutes at room
temperature. After washing in TBST, sections were
blocked with 5% normal goat serum (Vector Laborator-
ies, Burlingame, CA, USA; Catalog #S-1000) for 2 hours
at room temperature, and then dually incubated over-
night (at 4°C) with the following primary antibodies: a
mouse monoclonal antibody directed against NeuN
(A60; Abcam, Cambridge, MA, USA; Catalog #ab77315,
diluted 1:1000) and a rabbit polyclonal antibody di-
rected against oligomeric Aβ (A11; Chemicon, diluted
1:2000). Sections were then washed in TBST, and the
secondary antibodies were applied for 90 minutes at
room temperature in the dark: AlexaFluor 488 goat anti-
mouse IgG (Molecular Probes, Eugene, OR, USA; Catalog
#A-11001, diluted 1:1000) and AlexaFluor 594 goat anti-
rabbit IgG (Molecular Probes; Catalog #A-11012, diluted
1:1000). To eliminate possible lipofuscin autofluores-
cence, tissue sections were incubated in a 0.3% Sudan
Black B (Sigma-Aldrich, St. Louis, MO, USA; Catalog
#S-0395) solution in 70% ethanol for 20 minutes at
room temperature in the dark. Sections were washed in
distilled water and coverslipped using Vectashield Hard
Set Mounting Medium with DAPI (Vector Laboratories;
Catalog #H-1500). Primary antibody omission controls
were run alongside the other samples to check for non-
specific binding due to the secondary antibodies, and
advanced AD human prefrontal cortical sections were
run as positive controls.Masson trichrome staining
Masson trichrome staining was carried out in accord-
ance with well-characterized protocols [23,24]. Briefly,
tissue sections were deparaffinized and hydrated in
distilled water prior to a 1-hour treatment in Bouin’s
fixative (Richard-Allan Scientific; Catalog #NC9674780)
at 56°C. Sections were washed in running distilled water
until clear, and then stained in Weigert’s iron hematoxylin
(Richard-Allan Scientific; Catalog #NC9231529) for 10 -
minutes. Following a 10-minute wash in running water,
sections were stained in Biebrich scarlet-acid fuchsin
(Richard-Allan Scientific; Catalog #NC9424144) for 2 -
minutes. Sections were rinsed in distilled water followed
by a 10-minute differentiation in phosphomolybdic-
phosphotungstic acid (Richard-Allan Scientific; Catalog
#NC9443038). Aniline blue (Richard-Allan Scientific;
Catalog #NC9684104) was used as a counterstain for
10 minutes, and then sections were differentiated in 1%
acetic acid for 3 minutes. Sections were dehydrated
through a series of graded alcohols back to xylene, and
then coverslipped and sealed using Cytoseal XYL (Richard-
Allan Scientific).
Verhoeff-Van Gieson staining
The Verhoeff-Van Gieson staining protocol for elastic fi-
bers was performed using well-established protocols
[24,25]. Briefly, tissue sections were deparaffinized and
hydrated to distilled water followed by a1-hour incu-
bation in Verhoeff ’s working solution (Polysciences,
Warrington, PA, USA; Catalog #25089). Sections were
rinsed in running water, and then differentiated in 2%
ferric chloride (Sigma-Aldrich; Catalog #451649) for
2 minutes. Following a 10-minute wash in running water,
sections were treated with 5% aqueous sodium thio-
sulfate (Sigma-Aldrich; Catalog #S7026) for 1 minute.
Tissue sections were then washed in running water for
5 minutes, and counterstained with Van Gieson’s solution
(Poly Scientific, Bay Shore, NY, USA; Catalog #s289) for
3 minutes. Sections were quickly dehydrated through a
series of graded alcohols back to xylene, and then cover-
slipped and sealed using Cytoseal XYL (Richard-Allan
Scientific).
Microscopy, image acquisition & qualitative grading
All immunohistochemistry and histochemically-stained
slides were converted to digital images using Aperio
Scan Scope (Aperio Technologies, Vista, CA, USA) as
8-bit acquisitions of color. For confocal microscopy,
images were acquired with a Nikon C1si confocal micro-
scope (Nikon Inc., Melville, NY, USA) using 488 nm and
561 nm diode lasers. Serial optical sections were per-
formed with EZ-C1 computer software (Nikon Inc.). Z-
series sections were collected at 1.5 μm with a 20×
PlanApo lens and scan zoom of 2×. Each wavelength
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images were processed with Elements computer software
(Nikon Inc.). Pathology and morphological changes, as
observed in histochemically-stained sections, were quali-
tatively graded using a scale ranging from no detectable
changes (−), to mild (+), moderate (++), or severe (+++)
changes.
Results
All histological and immunohistochemical findings are
summarized in Table 1. The tgAPP21rats injected with
kaolin developed hydrocephalus similar to that reported
in our wild-type Sprague–Dawley rats [20]. Evans index
of ventricular size in the hydrocephalic tgAPP21 rats
was significantly larger than controls and was similar
to what we previously reported [10 weeks 0.30 ± 0.04
compared to sham-operated controls 0.19 ± 0.02
(mean ± SD)]. Figure 1 compares the ventricular and
aqueductal morphological changes observed in a typicalFigure 1 Sections of sham-operated and kaolin-injected rats 10 week
tgAPP21 rat (left panels) to a representative kaolin-injected tgAPP21rat (righ
striatum (A & B), the level of the hippocampus (C & D), and the level of the c
enlargement in the kaolin-treated tgAPP21 rat compared to sham-operated rahydrocephalic tgAPP21 rat to a typical age-matched sham-
operated control.
The hydrocephalus was due to an intense histiocytic
and granulomatous reaction in the SAS which was
largely resolved by six months, though some small
granulomas remained. Despite the resolution of the in-
flammation, scarring and blockage of the SAS remained
(Figure 2).
Aβ immunostaining showed a marked increase in
intraneuronal Aβ40 in the hippocampus and fronto-
parietal cortex compared to sham-operated controls
(Figure 3). No amyloid plaques were observed, but
diffuse cytoplasmic Aβ40 immunoreactivity was evident
across multiple neuronal populations. The absence of
dense-core plaques was not surprising given the absence
of Aβ42 accumulation.
Although Aβ42 is more apt to self-assemble, Aβ40 can
also self-assemble into oligomeric forms. Oligomeric Aβ
immunoreactivity was predominately confined to neuronss after injection. Comparison of a representative sham-operated
t panels) at three different coronal brain levels: the level of the
erebral aqueduct (E & F). Note the marked ventricular and aqueductal
t (arrows). H&E stain, ×10.
Figure 2 Effects of cisternal kaolin injection. (A) At 10 weeks post-kaolin injection, there is marked histiocytic and granulomatous inflammation
composed of many macrophages filled with kaolin in the SAS at the base of the brain (here around the hypothalamus and 3rd ventricle). (B) At six
months post-kaolin injection, the inflammation has subsided leaving scarring and blockage in the SAS (below the 3rd ventricle) and a few small
collections of histiocytes in the ventricle walls, here the 3rd ventricle (arrow). Masson trichrome stain, ×200.
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tgAPP21 rats (Figure 4).
In hydrocephalic tgAPP21 rats, compared to controls,
there was increased oligomeric Aβ immunoreactivity in
addition to the increase in Aβ 40 in both hippocampal
(data not shown) and cortical neurons at 10 weeks post-
hydrocephalus induction in 6 and 12-month-old animals
(Figure 5).
Vascular pathology was accelerated by the induction of
hydrocephalus compared to controls. In the six-month-
old rats, subtle degenerative changes were noted in
vessel walls at 10 weeks post-kaolin, whereas in the six-Figure 3 Immunohistochemical staining for Aβ40. (A) Hippocampal ne
minimal immunoreactivity evident 10 weeks after sham-surgery, x80. (B) Hi
10 weeks after kaolin injection demonstrating enhanced immunoreactiv
neurons (arrow) in a sham-operated six-month-old tgAPP21 rat at 10 w
(D) There is more robust neuronal immunoreactivity in the frontopariet
injection (arrow), ×200.month-old rat at six months post-kaolin and in the 12-
month-old rat 10 weeks post-kaolin, more pronounced
degenerative changes were seen with clear expansion of
the Virchow-Robin space in interstitial vessels (Figure 6).
Amyloid angiopathic changes were seen by immuno-
staining for Aβ40. These changes were more dramatic in
the 12-month-old tgAPP21 rats than in the six-month-
old rats, and in both sets of hydrocephalic rats, the dif-
ference from sham-operated controls was clearly evident
(Figure 7).
Seven of the tgAPP21 rats were allowed to reach their
natural end of life (approximately 30 months). Threeurons in a sham-operated six-month-old tgAPP21 rat (arrows). There is
ppocampal neurons in a hydrocephalic six-month-old tgAPP21 rat
ity in areas CA2 and CA3 (arrows), ×80. (C) Frontoparietal cortical
eeks post-surgery showing minimal Aβ40 immunoreactivity, ×200.
al cortex in six-month-old tgAPP21 rats 10 weeks following kaolin
Figure 4 Oligomeric Aβ immunoreactivity is intraneuronal. Top row: hippocampal NeuN (A) and oligomeric Aβ (B) immunoreactivity in a
six-month-old tgAPP21 rat at 10 weeks post-kaolin showing a strong overlap of immunopositive neuronal cell bodies (C), ×400. Bottom row:
Frontoparietal cortical NeuN (D) and oligomeric Aβ (E) immunoreactivity in a six-month-old tgAPP21 rat at 10 weeks post-kaolin also reveals a
widespread concomitance of immunopositive neuronal cell bodies (F), ×200.
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hydrocephalic tgAPP21 rats were found to have frequent
areas of microscopic cortical infarction in their brains
(Figure 8). In the non-kaolin controls, no infarcts were
seen.
Discussion
Clearance of macromolecules, such as Aβ, from the
brain interstitial space involves at least four different
pathways: i) via in situ degradation [26-30], ii) active
transport across the blood–brain barrier [31-36], iii)
across the choroid plexus epithelium by active trans-
port [37], and iv) via the production and turnover of
the CSF. CSF turnover is defined as the number of
times the CSF is renewed in 24 hours and is calculated
by dividing CSF production in 24 hours by the volume
of the CSF space [38-42]. Normally in humans, CSF
turnover occurs 4–5 times per day.
Hydrocephalus is known to disrupt normal CSF physio-
logical functions. In both AD and in hydrocephalic patients,CSF turnover is reduced threefold [6,43,44]. In both wild-
type rat models of NPH and in human NPH patients there-
fore, CSF clearance of potentially toxic solutes like Aβ is
significantly reduced, resulting in the accumulation of these
molecules in brain parenchyma. Several investigations in la-
boratory animals have described significantly decreased
CSF production and turnover after kaolin hydrocephalus
induction [45,46], and is also seen in humans with NPH
[44]. Resistance to CSF absorption is also increased in
hydrocephalus [47,48]. Despite eventual clearance of the in-
flammation produced by the kaolin, increased resistance to
CSF absorption and decreased compliance remain [47,48].
This study examined the effects of kaolin-induced
hydrocephalus on amyloid accumulation and vascular
pathology in a transgenic rat model of AD. The analysis
was carried out by qualitative histological and immuno-
histochemical staining, comparing the hydrocephalic
tgAPP21 brains to age-matched, sham-operated and
naïve controls. We found that induced hydrocephalus
accelerated Aβ accumulation in neurons and Aβ
Figure 5 Oligomeric Aβ in tgAPP21hydrocephalic rat frontoparietal cortex compared to control rat (arrows). Top row: six-month-old rat.
(A) sham-operated control brain showing minimal immunostaining for oligomeric forms, ×200. (B) six-month-old rat 10 weeks post-kaolin
hydrocephalus, ×200. There is a marked increase in immunoreactive product. Bottom row: 12-month-old rat. (C) sham-operated control showing
moderate immunoreactivity for oligomeric Aβ, ×200. (D) 12-month-old rat 10 weeks post-kaolin hydrocephalus showing a significant increase in
oligomeric Aβ, ×200.
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to decreased clearance of Aβ. Aβ immunostaining in
cerebral cortex and hippocampus was increased in the
hydrocephalic rats compared to controls, and amyloid
angiopathic degeneration of cerebral vessels was also ac-
celerated compared to controls. The amyloid angiopathy
associated with the hydrocephalic rats appeared to cause
microscopic ischemic infarcts not seen in the control
animals.
It is well known that there is variability in the degree
of hydrocephalus produced by intracisternal kaolin. AlsoFigure 6 Degenerative changes in hydrocephalic rat vessels compare
demonstrating a normal appearing parenchymal vessel. (B) six-month-old t
changes. (C) six-month-old tgAPP21 rat six months post hydrocephalus ind
and expansion of the Virchow-Robin space. Verhoeff-Van Gieson stain, ×20in any qualitative histological and immunohistochemical
study, fixation artifact must always be considered in
assessing changes. Therefore, comparison to both
sham-operated and naïve controls processed in exactly
the same way as the hydrocephalic rats, is essential to
identifying true differences from artifact. The micro-
scopic findings in the two groups (hydrocephalic
and controls) in this study were internally consistent but
were strikingly different in Aβ accumulation, self-assembly
into oligomeric forms and vascular pathology. Although
not quantitative, the group comparisons were sufficientlyd to controls (arrows). (A) Age-matched sham-operated control
gAPP21 rat at 10 weeks post-kaolin showing very subtle vascular
uction demonstrating rather marked vessel wall degenerative changes
0.
Figure 7 Deposition of Aβ40 in brain parenchymal vessels (arrows). Top row: six-month-old tgAPP21 rat. (A) sham-operated age-matched
control, x200. (B) Hydrocephalic tgAPP21 rat 10 weeks post kaolin injection, ×200. Note a moderate increase in immunoreactivity in the vessels of
the hydrocephalic rat compared to control. Bottom row: 12-month-old tgAPP21 rat. (C) Age-matched, sham-operated control showing minimal
vascular Aβ immunostaining, x200. (D) 12-month-old tgAPP21 rat 10 weeks after hydrocephalus induction showing marked deposition of Aβ in
vessel walls, ×200.
Silverberg et al. Fluids and Barriers of the CNS 2015, 12:2 Page 9 of 11
http://www.fluidsbarrierscns.com/content/12/1/2different to conclude that accelerated amyloid deposition
and vascular pathology occurs in tgAPP21 rats with
kaolin-induced hydrocephalus.
One can argue that the tgAPP21 rat is more a model
for amyloid angiopathy [49] rather than AD, in that
there is no increase in Aβ42 concentrations and no
amyloid plaque formation was evident. Instead we see
that the predominantly expressed Aβ40 accumulatesFigure 8 Evidence of cortical infarcts in hydrocephalic tgAPP21
rats. Frontoparietal cortex stained for Aβ40. Arrows point to areas of
infarction, ×200.in the cerebral microvessels, reportedly localized to
the basement membrane [50,51]. However, our study
was meant to explore whether the CSF plays a signifi-
cant role in the clearance of macromolecular solutes
from the brain interstitial space, and whether its
failure in chronic hydrocephalus accelerates the accu-
mulation of many brain metabolites. The present
study suggests that this is the case in rats and likely in
humans as well.Conclusions
The results of this study underscore the importance of
normal CSF physiologic functions in clearing poten-
tially toxic macromolecules from the brain. The study
shows that kaolin-induced hydrocephalus can acceler-
ate intraneuronal Aβ accumulation and self-assembly,
and accelerate vascular pathology in tgAPP21 rats. In
addition, it demonstrates that disrupted CSF produc-
tion and turnover results in impaired Aβ clearance
from the brain and accelerates vascular pathology in
chronic hydrocephalus. The high co-morbidity seen in
NPH, AD and CVD is likely not an age-related coinci-
dence, but rather a convergence of pathologies related
to reduced solute clearance.
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